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Abstract
Melanomas are disease entities driven in part by the mitogen activated protein kinase (MAPK) pathway. The TCGA network recently
defined four genetic subtypes based on the most prevalent significantly mutated genes, including mutant BRAF, mutant RAS (N/H/K),
mutant NF1, and Triple wild-type melanoma (harboring none of the aforementioned mutations, but instead includes KIT, GNA and
GNAQ mutations).
The successful development of kinase inhibitors marked a milestone in the treatment of metastatic melanoma. Combination treatment
with a BRAF- and MEK-inhibitor is the current standard of care for inoperable stage IIIC/IV BRAF-mutated melanoma. Recent data
demonstrate excellent long-term outcome, especially in patients with normal baseline LDH levels, and confirm that there is a subset of
BRAF inhibitor-naive patients who experience durable responses without progression on combination treatment. In the future, adding a
third compound based on individual genetic alterations might further improve the outcome of targeted therapy.
 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
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Introduction
In the past decade, revolutionary insights were made in
understanding and treating melanoma. The identification of
the critical role of the mitogen activated protein kinase
(MAPK) pathway and development of targeted therapy
dramatically changed prognosis and overall survival (OS)
of metastatic melanoma patients.1,2 Novel techniques
such as next generation sequencing enable the identification
of new cancer “driver” genes and their mutations. These
new insights contribute to prognostication and create
opportunities for development of innovative mutation-
directed therapies.
Sequencing data have shown that the median mutation
rate in melanoma is >10 mutations/Mb, the highest of all
cancers so far analyzed by The Cancer Genome Atlas
(TCGA) network.3 Nevertheless, the number of mutations
differs according to the site, with the lowest rate in primary
melanomas on non-ultraviolet-exposed non-glabrous skin
and the highest in patients with history of chronic sun expo-
sure.4 Genetic alterations in melanoma oncogenes and tu-
mor suppressor genes commonly cause constitutive
signaling through RAS-RAF-MEK-ERK, also known as
the MAPK pathway.5,6 This cascade concludes in activation
of ERK1 and ERK2, which can then translocate to the nu-
cleus and regulate MITF, c-MYC and other transcription
factors, resulting in alteration of cell proliferation and
senescence (Fig. 1).6 Less frequently identified, yet also
relevant are genetic aberrations in other cellular pathways,
such as cell cycle control (CDKN2A), apoptosis (PT53) and
the PI3K pathway (TERT, PTEN).7e10 In 2015, TCGA
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Network suggested a new genomic classification for mela-
noma based on the most prevalent significantly mutated
genes: mutant BRAF, mutant RAS, mutant NF1 and triple
wild-type (triple wt) melanoma.7
Genetic landscape of mutations
The most common genetic alteration, accounting for
around 50% of all somatic mutations in cutaneous mela-
noma, is activating mutation of serineethreonine kinase
BRAF gene.7,8,11 This causes constitutive activation of
BRAF protein, which results in increased proliferation
and survival of melanoma cells.12 In more than 90% of
cases valine is substituted with glutamate at codon 600
(V600E), less frequently with lysine (V600K) or arginine
(V600R).5,7 Interestingly, patients with BRAF mutations
are generally younger. It is most frequent in cutaneous mel-
anoma, while it’s detected in only 10e20% of mucosal
melanoma.5
RAS is a member of the guanosine 50-triphosphatase
(GTP)-binding protein family. Under normal conditions,
RAS activation is induced by extracellular signaling and
is reversible. It’s driven by guanine nucleotide exchange
factor, which results in exchange of protein-bound guano-
sine diphosphate (GDP) to triphosphate (GTP). Mutations
in the RAS gene impair inactivation and keep RAS protein
in the activated state.13 The active form, RAS-GTP, initiates
phosphorylation of RAF and subsequently MEK and ERK
and leads to the activation of the MAPK pathway.13 This
specific structure causes difficulties in targeting; hence,
RAS was named the “undruggable” target.13 RAS mutations
are found in around 30% of melanomas and usually affect
NRAS (Q61R, Q61K, and Q61H).7,11,14 RAS not only acti-
vates the MAPK pathway, but also has activators and effec-
tors among other cellular pathways such as
phosphatidylinositol-3 kinases (PI3K), T-Cell Lymphoma
Invasion and Metastasis 1 (TIAM1) and others.13
The third most frequently identified genetic mutation is
located in the NF1 tumor suppressor gene, which serves as
a regulator of RAS through GTP-ase activating protein.
Due to an inactivating mutation, the regulative properties
of NF1 are lost, which results in continuous activation of
RAS.15 This mutation was observed in 14% of samples
analyzed by TCGA,7 and in 46.4% of BRAF and NRAS
Figure 1. (Oncogenes shown in green, tumor suppressors shown in red) Extracellular signals such as EGF (epidermal growth factor), FGF (fibroblast growth
factor), PDGF (platelet derived growth factor) or HGF (hepatocyte growth factor) bind to corresponding receptors (EGFR, FGFR, PDGFR and c-Myc, respec-
tively) and induce signal transduction, which results in activation of RAS (exchange of protein-bound GDP (inactive form) to GTP (active form), accelerated
by guanine nucleotide exchange factors).13 NF1 negatively regulates RAS by increasing RAS GTPase activity and hence turning RAS-GTP to RAS-GDP.8
Active RAS leads to activation of BRAF (dimerization of non-mutated BRAF; BRAF V600E mutated protein can be active as a monomer) and subsequently
MEK. This cascade concludes in activation of ERK1 and ERK2, which can then translocate to the nucleus and regulate MITF, c-MYC and other transcription
factors, resulting in alteration of cell proliferation and senescence.6 Receptor tyrosine kinases (RTK) or RAS-GTP can activate the PI3K-AKT pathway, while
PTEN is a negative regulator, mutation of which leads to constitutive activation of AKT and is followed by changes in cell growth, motility and invasion.124
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wt melanomas analyzed by Krauthammer et al.8 Interest-
ingly, around 60% of these melanomas harbored co-
mutations in RAS-opathy genes (RASA2, PTPN11, SOS1,
RAF1 and SPRED1),8,16 which are known to be linked
with Noonan, Leopard and Legius syndromes.8
Melanomas referred to as triple wt show none of the
three previously mentioned mutations. This subgroup in-
cludes GNAQ, commonly found in uveal melanoma, or
KIT mutations. Interestingly, only 30% of triple wt mela-
nomas harbor a UV signature, compared to over 90% of
BRAF-, RAS- and NF1-subtypes, but more copy number
changes and complex structural arrangements are identified
in triple wt.7
Identifying mutations open opportunities for the devel-
opment of new therapeutic agents, identification of predic-
tive biomarkers and aid in understanding of melanoma
genesis. Shain et al. evaluated genetic alterations in 37 pri-
mary melanomas and their adjacent antecedent lesions.17
Interestingly, histologically benign lesions harbored
V600E mutations only, while intermediate lesions harbored
additional BRAF as well as NRAS mutations. Compared to
benign and intermediate lesions, more Telomerase reverse
transcriptase (TERT ) promoter and copy-number alter-
ations were identified in melanoma, whereas Phosphatase
and tensin homolog (PTEN ) and tumor protein p53
(TP53) mutations were only found in advanced primary
melanomas.7,17 This suggests that BRAF mutations are suf-
ficient for nevus formation, but additional oncogenic alter-
ations are needed for malignant transformation.
Driver mutations as prognostic factors in melanoma?
One of the major questions raised in the last years is
whether the identification of driver mutations has prog-
nostic or predictive clinical significance.
Long et al. were initially able to demonstrate an associ-
ation between BRAF mutations and inferior clinical
outcome in a prospective cohort of 197 Australian mela-
noma patients, albeit with no influence on disease free sur-
vival (DFS).18 Similarly, NRAS mutant melanoma patients
were also reported to have impaired survival with a higher
incidence of central nervous system (CNS) involvement in
a retrospective setting; however no difference in overall
survival (OS) between BRAF mutated and wt melanomas
was noted.19
Since then, several studies have been conducted, none of
which were able to show an influence of BRAF or NRAS
mutation status on OS.20e26
A subsequent prospective Australian study (n ¼ 308)
was not able to confirm the previously reported impact on
OS of BRAF mutant melanoma patients. However, one-
year survival from diagnosis of metastasis was significantly
longer for patients with BRAF mutant melanoma treated
with a kinase inhibitor than those without (29%,
p < 0.001), or for BRAF wt patients (37%, p < 0.001).27
Similarly, Frauchiger et al. confirmed that BRAF mutant
melanoma patients treated with selective kinase inhibitors
have a statistically significant longer OS compared to wt
patients (OS 14.5 vs 10.6 months, p ¼ 0.14).24
Relating to immunotherapy, it has recently been shown
that harboring an NRAS mutation increases the response
rate (RR) to checkpoint inhibitors with no significant
impact on OS and progression-free survival (PFS).28,29 A
recent retrospective study affirmed this assumption:
although mutational status had no influence on OS in
anti-CTLA-4 treated patients, a non-statistically-
significant trend for superior clinical outcome in NRAS
mutant patients was observed.30
As outlined previously, the third most commonly re-
ported mutation is the inactivating mutation of NF1, which
shows similar OS compared to BRAF-mutant, NRAS-
mutant or triple wt melanomas.8 No correlation between
the loss of NF1 and response to treatment with MEK or
ERK inhibitors has been noted in vitro so far.8 Neverthe-
less, further large prospective clinical trials are needed to
address this issue.
Besides these most commonly observed mutations in
melanoma, other features seem to have prognostic impact.
TERT promoter mutations are associated with impaired
OS in cutaneous compared to acral, mucosal and uveal mel-
anomas31 and are present in approximately 70e80% of
BRAF-, NRAS- and NF1- compared to 7% of triple wt mel-
anomas.7 Furthermore, they were found in 61% of fast-
growing compared to 32% of slow-growing melanomas
(p ¼ <0.0001).32 Thus, it was suggested that the presence
of TERT promoter mutations can partly explain a more
aggressive clinical outcome, associated with an accelerated
growth rate. In contrast, BRAF and NRAS hotspot mutations
have not been found to be associated with increased
growth. Therefore, TERT promoter mutation may serve as
a future biomarker to identify aggressive tumors, which
could benefit from adjuvant treatment.
The prognostic significance of PTEN promoter methyl-
ation in clinical outcome of melanoma patients was
recently elucidated.9,33 In a cohort of 392 melanoma pa-
tients, PTEN was identified as an independent predictor
for impaired survival, highlighting potential therapeutic op-
portunities in this field.9
In summary, the mutation status alone does not seem to
be sufficient to predict the outcome of advanced melanoma
patients and cannot be used as an independent prognostic
factor. However, the identification of other genetic features
and their eventual prognostic significance are fundamental
steps in the field of melanoma management.
Multi-kinase inhibitors
Tyrosine kinase inhibitors
Among targeted therapies, monoclonal antibodies
(mAbs) and small-molecule inhibitors (SMIs) of multiple
tyrosine kinase activity present as ideal candidates for
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melanoma treatment.34 Tyrosine kinase inhibitors (TKIs)
block vital pathways in the context of cell growth and sur-
vival via binding to small intercellular molecules, which are
common phosphorylation sites of kinases (most commonly
tyrosine or serineethreonine kinases) that are either associ-
ated with growth factor receptors or downstream signaling
molecules. Several clinical trials have been performed over
the last years either with single agents or in combination
with chemotherapy. However, the demonstrated clinical
benefit with multi-targeted tyrosine kinase inhibitors
(mTKIs) was limited compared to selective BRAF and
MEK inhibitors.
Sorafenib
Sorafenib is an orally available, broad-spectrum mTKI
with anti-proliferative and anti-angiogenic effects.35 Sora-
fenib targets several RAF isoforms as well as other receptor
tyrosine kinase inhibitors (RTKI) like vascular endothelial
growth factor (VEGFR 2/3), platelet-derived growth factor
receptor beta (PDGFR-b), fms-related tyrosine kinase 3
(FLT-3) and c-KIT.30,35
In clinical trials with advanced melanoma patients, sor-
afenib showed no clinical benefit as a single agent.36,37 In
the context of evaluating combination therapies, Flaherty
et al. presented encouraging preliminary results of sorafe-
nib combined with carboplatin and paclitaxel (CP).38 The
combination showed a 37% partial response (PR) rate in
the interim analysis while another 48% demonstrated stable
disease (SD).38 Nevertheless, phase III clinical trials failed
to show significant benefit.39,40
In addition, several phase I/II studies with sorafenib in
combination with dacarbazine (DTIC) or temozolomide
(TMZ) showed low anti-tumor activity and mainly achieved
SD.41e43 The beneficial 45.5% overall metabolic RR (PER-
CIST criteria) in a recent clinical trial did not result in last-
ing objective responses.44 Sorafenib in combination with
CP in uveal melanoma patients also failed to achieve clin-
ical benefit with the study being terminated early (PFS 4
months, OS 11 months, no confirmed objective tumor re-
sponses by RECIST criteria).45 However, the results of
the STREAM study in chemo-naive metastatic uveal mela-
noma patients are still pending.46
In general, sorafenib monotherapy and combination
therapies had a manageable toxicity profile, with the major-
ity of adverse events (AEs) being mild.36,37,39e41,47 Severe
adverse events (SAE) were reported in 51% of patients,
with the most common being hematologic toxicities.47
The most commonly observed drug-related AEs under sor-
afenib monotherapy were skin reactions (rash and palmar-
plantar erythrodysesthesia syndrome), gastrointestinal and
constitutional disorders (corresponding grade 1e2 inten-
sity).36,37 Combination treatments with sorafenib led to
hematotoxicity, fatigue, sensory neuropathy and skin
reactions.39,40,43
Based on the limited activity of sorafenib, doubts were
raised concerning the potential of RAF inhibition as a
therapeutic option. Therapeutic failure of sorafenib in
advanced melanoma was likely due to an inability to selec-
tively achieve RAF inhibition at maximum tolerated doses.
Subsequent trials with selective BRAF inhibitors (BRAFi)
followed, changing the era of melanoma treatment.
Pazopanib
Pazopanib is another orally-bioavailable, adenosine tri-
phosphate (ATP)-competitive TKI with selectivity for
VEGFR-1, -2, and -3, FDA-approved for renal carcinoma
and soft tissue sarcoma in 2009.48 Furthermore, it blocks
the PDGFR-a and eb as well as c-KIT.
Clinical trials in melanoma patients with pazopanib are
limited. None of the studies published so far reported sig-
nificant clinical benefit in advanced BRAF wt melanoma
patients.49,50 A recent single-center pilot study investi-
gating the metabolic response, the early cytokine and che-
mokine profile and the histological findings of metastatic
tissue under pazopanib and paclitaxel in the second line
setting showed moderate efficacy.51 17 patients with stage
III or IV melanoma were included. 5 out of 14 evaluable
patients showed partial metabolic response (using PRE-
CIST 1.0 criteria) after 10 days of pazopanib monotherapy.
No response was achieved at day 70 of combination treat-
ment. The median progression-free survival (mPFS) was
70 days, the median overall survival (mOS) 208 days.51
The drug was generally well tolerated with 87% of all AEs
being mild to moderate, such as loss of appetite, weakness,
skin reactions, bone marrow function impairment and neuro-
logical symptoms. 13% of AEs were grade 3 or grade 4.
Other multi-kinase inhibitors
Axitinib, another tyrosine kinase inhibitor against
VEGFR-1, -2, -3, PDGFR-b and c-KIT, showed promising
activity in combination with carboplatin and paclitaxel in
wt metastatic melanoma patients in a phase II clinical study
(RR 18.8%, 6-month-PFS of 33.9%).52 However, these
result warrants further testing in randomized phase III tri-
als. On the other hand, the multi-kinase inhibitor Lenvatinib
(E7080) achieved limited responses both in monotherapy
and in combination with TMZ in the phase I setting.53
KIT inhibitors
The KIT receptor protein tyrosine kinase is a transmem-
brane protein consisting of extra- and intracellular binding
domains and a signal transmembrane region. Most KIT mu-
tations are located in exon 11, which codes for the juxta-
membrane domain, and in exon 13, which codes for a
kinase domain.
Although amplifications or activating mutations of KIT
are generally rare in melanoma, they are more commonly
found in mucosal, acral and in melanomas arising from
chronically sun damaged-skin.54 As the number of
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advanced melanoma patients harboring KIT mutations is
low, the clinical experience of KIT inhibitors is limited.
The most widely investigated KIT inhibitor is imatinib,
which is FDA-approved for gastrointestinal stromal tumors
(GIST) and dermatofibrosarcoma protuberans.
Out of 51 KIT mutant melanoma patients in a phase II
clinical trial, 28 patients were treated with imatinib
400 mg orally bid. The overall response rate (ORR) was
16% with a median OS of 46.3 weeks.55 In a phase II clin-
ical trial of 43 KIT mutant melanoma patients, 23 had an
ORR (10 patients achieved PR and 13 SD).56 1-year OS
was 51%, 6-month PFS rate was 36.6%. The best predictor
of treatment response in both trials was the presence of mu-
tation in c-KIT exons 11 and 13. Most frequently observed
adverse events were hematologic toxicities (leukopenia and
anemia), fatigue, nausea, rash and periorbital edema.
Nilotinib is a BCR-ABL1 TKI that was rationally de-
signed to have increased potency and selectivity for the
oncogene BCR-ABL1. It also inhibits c-KIT with greater
potency than imatinib and is effective against several
known c-KIT mutations in vitro.57,58 Nilotinib achieved a
satisfactory disease control rate (DCR) in a phase II clinical
study of twenty-seven melanoma patients that had pro-
gressed on imatinib or in patients with brain metastases
(4-month DCR 27% and 12.5%, respectively).59
The effect of nilotinib (400 mg bid) was investigated in
another open-label single-arm clinical trial (TEAM Trial,
submitted for publication).60 Similarly, among 42 patients
in the nilotinib arm, the ORR was 26.2% (95% CI,
13.9%e42.0%; PRs, n ¼ 11; complete response (CR),
n ¼ 0). The median PFS was 4.2 months (95% CI,
2.1e5.8 months). At 6 months, the estimated PFS rate
was 34.6% (95% CI, 20.2%e49.3%).
Monoclonal antibodies
Bevacizumab
The prognostic implications of overexpression of VEGF
in clinical outcome and disease progression in melanoma
remain controversial.61 VEGF is assumed to be the domi-
nant growth factor in angiogenesis.62 The relevance of
angiogenesis/neoangiogenesis in tumor metabolism, prolif-
eration and the tumor microenvironment is unquestioned,63
thus the inhibition of the VEGF pathway offers a promising
therapeutic approach.
Bevacizumab, a monoclonal antibody against VEGF-A,
was the first anti-angiogenic agent on the market. It has
been approved for breast neoplasms, non-small cell lung
cancer, renal, ovarian, cervix and colorectal cancer.64 Ac-
cording to a recently published phase II clinical study,
nab-paclitaxel in combination with bevacizumab showed
an ORR of 36% in unresectable stage III and IV melanoma
patients (n ¼ 50) in a first line setting.65 The following
multicenter phase II clinical trial combining temozolomide
(TMZ) with bevacizumab showed limited efficacy.66 On the
other hand, current phase I/II clinical trials of bevacizumab
in combination with ipilimumab, erlotinib or imatinib
demonstrated no synergistic effect.67e69 Nevertheless,
well-controlled phase III clinical trials are warranted to
further investigate these results.
Tendency in clinical research opts in favor of combina-
tion therapies, since a certain immunomodulatory effect of
TKIs seems to be existent.70,71 Summarizing the literature,
multi-targeted TKI are not established as standard treat-
ment of advanced melanoma but are still discussed as po-
tential second line options in BRAF- and NRAS wt
melanoma patients.93
Etaracizumab
Etaracizumab (MEDI-522), a monoclonal antibody
against Integrin alphavbeta3, resulted in similar OS and
PFS rates when compared to combination with DTIC
(12.6 versus 9.4 months, respectively)72 and was not further
investigated in a phase III setting.
Intetumumab
The anti-aV-integrin monoclonal antibody showed only
a nonsignificant trend towards an improved OS in a ran-
domized phase II trial compared to DTIC.73
mTOR-inhibitors
Since the mammalian target of rapamycin (mTOR)
signaling is upregulated in metastatic melanoma, drugs tar-
geting mTOR seem to represent promising therapeutic tar-
gets. Everolimus (RAD-001), an orally administered
inhibitor of mTOR, achieved only SD as best ORR in a
cohort of 20 metastatic melanoma patients with a PFS of
3 months.74 It failed to show significant objective responses
in combination with TMZ over TMZ alone.75 A phase II
clinical study of Everolimus in combination with pasireo-
tide didn’t meet its primary endpoint in uveal metastatic
melanoma.76
Kinase inhibitors
Early developments
The successful development of kinase inhibitors marked
a milestone in the treatment of metastatic melanoma. Until
2010, no systemic treatment had demonstrated any
improvement of overall survival in metastatic melanoma.
Tsai et al. first discovered a potent, selective inhibitor of
BRAF V600E, using a scaffold-based drug design
approach.77 In preclinical studies, this compound showed
impressive antitumor activity in BRAF V600E mutated
cell lines by inducing cell cycle arrest and apoptosis, with
no such effect on BRAF wt cell lines. Oral administration
in xenograft models harboring the V600E mutation resulted
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in a substantial block of tumor growth and clinical regres-
sion without any apparent toxicity.77,78 Early clinical trials
confirmed that BRAF inhibition did in fact cause complete
or partial tumor regression in a large portion of patients
harboring the BRAF V600 mutation.79,80
BRAF inhibition
BRAF inhibition rapidly became standard of care in
BRAF mutated melanoma patients. Vemurafenib is an
orally bioavailable, ATP-competitive, small-molecule
(489.92 Da) inhibitor of BRAF. Dabrafenib (519.56 Da)
and encorafenib (540.01 Da) are similar molecules. The
change in paradigm of treatment of advanced melanoma
is mainly based on the results of the following two pivotal
trials.
The international, multicenter phase III randomized clin-
ical trial comparing vemurafenib to the reference chemo-
therapy dacarbazine (BRIM-3) showed a significantly
longer mOS in the vemurafenib group (13.6 months [95%
CI 12.0e15.2] vs 9.7 months [7.9e12.8]; hazard ratio
[HR] 0.70 [95% CI 0.57e0.87]; p ¼ 0.0008), as well as a
significantly increased mPFS (6.9 months [95% CI
6.1e7.0] vs 1.6 months [1.6e2.1]; HR 0.38 [95% CI
0.32e0.46]; p < 0.0001). OS and PFS were significantly
shorter in patients with increased LDH levels at baseline
in both groups. The RR amounted to 57% in the vemurafe-
nib group vs. 9% in the dacarbazine group.81,82 Following
this phase III trial, vemurafenib was approved by the
FDA in 2011 for treatment of Stage IIIC and IV metastatic
melanoma patients harboring a BRAF V600E mutation.
Moreover, the multicenter phase III randomized clinical
trial evaluating the BRAFi dabrafenib vs. dacarbazine
(BREAK-3) showed comparable results, with a mPFS of
6.9 months for dabrafenib vs. 2.7 months for dacarbazine,
hazard ratio (HR) 0.37 (95% CI 0.23e0.57; p < 0.0001).
The mOS in this study at last update was at 18.2 months
vs. 15.6 months, HR 0.76 (95% CI 0.48e1.21). The ORR
was 50% in the dabrafenib group and 6% in the dacarbazine
group.83,84 Dabrafenib received FDA approval in 2013.
Common AEs of BRAFi monotherapy with vemurafenib
include arthralgia (56% of patients), rash (41%), fatigue
(46%) and UVA-dependent photosensitivity (41%).85 The
most frequent grade 3e4 side effects include cutaneous
squamous cell carcinoma (19%) and keratoacanthoma
(10%), rash (9%) as well as abnormal liver function tests
(11%). Interestingly, 2.4% of patients developed a new pri-
mary melanoma during treatment.86 Treatment discontinu-
ation due to SAEs occurred in 7% of patients on
vemurafenib.81,82 Common side effects of dabrafenib
monotherapy comprise cutaneous AEs (hyperkeratosis
36%, alopecia 27%, skin papilloma 22%, palmar-plantar
hyperkeratosis 19%, rash 30%), pyrexia (16%), fatigue
(18%), headache (18%) and arthralgia (19%). 10% of pa-
tients developed cutaneous squamous cell carcinoma or
keratoacanthoma. Treatment discontinuation due to SAEs
occurred in 3% of dabrafenib patients.83,84 The most com-
mon grade 3e4 AEs for dabrafenib include cutaneous squa-
mous cell carcinoma (7%) and pyrexia (3%). Direct
comparison of AEs in these phase III trials is difficult. In
general, dabrafenib monotherapy exhibited a much lower
rate of photosensitivity (2%) compared to vemurafenib
(41%), as it has UVA-absorbing properties, while other
BRAF inhibitors do not.85 Further, dabrafenib showed a
lower rate of cutaneous malignancies, while exhibiting a
higher frequency of pyrexia.
In summary, BRAF inhibition proved to be very effica-
cious in BRAF-mutated patients, with a high response
rate and a rapid onset of response, but BRAFi monotherapy
is almost invariably followed by relapse due to acquired
drug resistance, most likely as a result of reactivation of
MEK and ERK.87e89
MEK inhibition
After observing that BRAF mutation is associated with
an increased and selective sensitivity to MEK inhibition
compared to BRAF-wt cells, Solit et al. suggested that
BRAF mutant tumors were dependent on MEK activity
and thus proposed MEK inhibition as a possible treatment
for metastatic melanoma.90 Initial trials with MEK inhibi-
tors (MEKi) confirmed this observation.91 MEKi are orally
bioavailable, non-ATP competitive, allosteric binding in-
hibitors of MEK. While trametinib (615.39 Da) and bini-
metinib (441.23 Da) inhibit MEK 1 and 2, cobimetinib
(531.31 Da) inhibits MEK1 only.
After positive phase I and II trials, monotherapy with
trametinib in BRAF mutant melanoma was investigated in
a phase III multicenter open-label trial. Chemotherapy
with dacarbazine or paclitaxel served as a comparison.
The mPFS was significantly prolonged compared to
chemotherapy (4.8 months vs. 1.5 months, HR 0.45 [95%
CI 0.33 to 0.63; p < 0.001]). The rate of OS at 6 months
improved as well, with 81% in the trametinib group and
67% in the chemotherapy group despite crossover (HR
0.54) [95% CI 0.32 to 0.92; p ¼ 0.01].92
In a phase II trial, MEKi monotherapy with binimetinib
was evaluated in patients with NRAS as well as in patients
with BRAF mutation, with a similar RR of 20% in BRAF-
and NRAS-mutated patients. Thus, MEK inhibition was the
first targeted therapy to show activity in patients harboring
an NRAS mutation. The median PFS was 3.7 months in pa-
tients with NRAS-mutated melanoma [95% CI 2.5e5.4] and
3.6 months [95% CI 2.0e3.8] in patients with BRAF-
mutated melanoma. The difference in PFS between this
and the aforementioned study might be explained by the
fact that patients previously treated with ipilimumab or
BRAF inhibitors were included in this trial, while being
excluded from the aforementioned one. Of note, this study
also showed evidence of MEKi activity in brain metasta-
ses.93 An ongoing phase III clinical trial of binimetinib in
patients with advanced NRAS-mutant melanoma (NEMO)
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recently met its primary endpoint of improving
progression-free survival compared to dacarbazine, with a
median PFS of 2.8 months for binimetinib versus 1.5
months for dacarbazine; HR 0.62, [95% CI 0.47e0.80],
p < 0.001.94
While MEK inhibition did show improvement in both
PFS and OS, the RRs seem to be inferior to those shown
for BRAF inhibitors. The molecular basis for this phenom-
enon remains unclear.
The side effect profile of MEKi differs greatly from
BRAFi. The most common AEs with trametinib were
rash (57%), diarrhea (43%) and peripheral edema (26%).
Frequent grade 3e4 AEs include hypertension (12%),
rash (8%) and fatigue (4%). Further side effects were fa-
tigue, acneiform dermatitis, nausea, alopecia, hypertension,
constipation and vomiting. Moreover, asymptomatic and
reversible reduction in left ventricular ejection fraction
(LVEF) and ocular toxic effects (blurred vision, reversible
chorioretinopathy) were observed.95 Dose interruptions
due to AEs occurred in 35% of patients. However, MEK in-
hibition did not seem to cause any cutaneous squamous-cell
carcinomas or hyperproliferative skin lesions.92 While both
classes have been known to cause a rash, MEKi seem to
cause a papulopustular rash, while BRAFi cause a hyper-
keratotic maculopapular rash.96
In addition, MEK inhibition was evaluated in combina-
tion with chemotherapy.97 However, there was no evidence
for an increase in efficacy compared to MEKi monother-
apy; hence, this was not evaluated in any further trials.
Combined BRAF- and MEK inhibition
With BRAF andMEK inhibitors both showing efficacy in
melanoma, preclinical studies suggested an enhanced anti-
tumor effect and a reduction of BRAFi-induced cutaneous
SCCwhen combining the two classes. Due to emerging resis-
tance to BRAFi as a result of MEK-ERK signaling reactiva-
tion, patients inevitably experience relapse.87,88 The effect of
MEKi treatment after treatment resistance to BRAFi in pa-
tients harboring a BRAF mutation was evaluated in a small
cohort of patients, with no significant response.93,98
In contrast, early trials evaluating the combination of
BRAFi and MEKi were very promising (Table 1). A ran-
domized phase I/II clinical trial comparing the combination
of dabrafenib and trametinib vs. dabrafenib alone (COMBI-
d) showed a marked increase in PFS in the combination
group (9.4 months vs. 5.8 months, HR 0.39 [95% CI
0.25e0.62; p < 0.001]) and a higher RR (76% complete
or partial response vs. 54% in the monotherapy group
(p ¼ 0.03)).99
Subsequently, phase III of the abovementioned trial
(COMBI-d) confirmed the superiority of BRAF and MEKi
combination, with a significantly prolonged mPFS of 11.0
months (95% CI 8.0e13.9) in the dabrafenib and trametinib
group vs. 8.8 months (5.9e9.3) in the dabrafenib monother-
apy group (HR 0.67, 95% CI 0.53e0.84; p ¼ 0.0004). The
ORR were at 69% for combination vs 53% for monotherapy
(p ¼ 0.0014), while the mOS was 25.1 months (95% CI
19.2enot reached) for the combination and 18.7 months
(15.2e23.7) for monotherapy (hazard ratio [HR] 0.71, 95%
CI 0.55e0.92; p ¼ 0.0107).100 A recent survival update
showed landmark OS rates of 52% at 2 years and 44% at 3
years.101 The best outcome was seen in patients with normal
LDH levels and less than three disease sites.
Another open-label, phase III trial comparing the combi-
nation of dabrafenib and trametinib vs. vemurafenib mono-
therapy (COMBI-v) was able to produce comparable
results. The mPFS amounted to 11.4 months in the combi-
nation group and 7.3 months in the vemurafenib group (HR
0.56; 95% CI, 0.46 to 0.69; p < 0.001). The ORR was 64%
in the combination and 51% in the vemurafenib group
(p < 0.001).102 Most important, quality of life was rated
significantly better in the combination group using three
standardized questionnaires measuring health-related qual-
ity of life during treatment and at disease progression.103
Finally, a phase III clinical trial investigating the combi-
nation of vemurafenib and cobimetinib vs. vemurafenib and
placebo (coBRIM) found a significant difference in mPFS
(9.9 months in the combination group vs. 6.2 months in
the control group (HR 0.51; [95% CI 0.39 to 0.68;
p < 0.001])) and a significantly higher ORR of 68% in
the combination group vs. 45% in the BRAF monotherapy
group (p < 0.001).104 The vemurafenib and cobimetinib
combination reached a mOS of 22.3 months [95% CI:
20.3-not reached], compared to 17.4 months for vemurafe-
nib alone [95% CI: 15.0e19.8], HR: 0.70; 95% CI:
0.55e0.90, p ¼ 0.005. The OS benefit was seen in all
groups, including patients with high LDH at baseline.105
Table 1
Outcome of combined BRAF and MEK inhibition of several landmark studies.
Study Phase Experimental (combination) arm mPFS (months) mOS (months) 1-yr OS (%) 2-yr OS (%) 3-yr OS (%) Ref.
BRIM7 I Vemurafenib, Cobimetinib 13.8 31.2 83 64 37 106
coBRIM III Vemurafenib, Cobimetinib 9.9 22.3 n/a n/a n/a 105
Combi D II Dabrafenib, Trametinib 9.4 n/a 72 60 47 99,107
Combi D III Dabrafenib, Trametinib 11.0 25.1 74 51 44 100,101
Combi V III Dabrafenib, Trametinib 11.4 26.1 72 53 45 102,134
COLUMBUS III Encorafenib, Binimetinib 14.9 n/a n/a n/a n/a 111
7V.C. Amann et al. / EJSO xx (2016) 1e13
Please cite this article in press as: Amann VC, et al., Developments in targeted therapy in melanoma, Eur J Surg Oncol (2016), http://dx.doi.org/10.1016/
j.ejso.2016.10.014
These data are supported by recent extended follow-up
results of a phase Ib trial of vemurafenib and cobimetinib
(BRIM7), with landmark survival for BRAF na€ıve patients
of 82%, 64%, and 37%, respectively at 1, 2, and 3 years,
and a mOS of 31.2 months.106
Addressing the question of long-term benefit, a recent
update on the randomized, phase II COMBI-d trial demon-
strated that there is, in fact, a subset of BRAFi-naive pa-
tients who experience long-term responses without
progression on combination treatment. Normal baseline
LDH levels were associated with a continued long term
response. Prolonged survival was associated with normal
baseline LDH levels and with fewer than 3 affected organ
sites. The OS at 1, 2, and 3 years for BRAFi-naive patients
receiving dabrafenib at standard dose 150 mg bid and tra-
metinib 2 mg qd was 72%, 60%, and 47%, respectively.
In the population with normal baseline LDH levels, OS at
1, 2, and 3 years was 88%, 75%, and 62%, respectively,
with a HR of 0.25 (0.12e0.53).107 Thus, long term OS rates
for BRAF/MEKi combination are similar to OS rates for
first line anti-PD1 treatment.108 The OS may have been
impacted by subsequent immunotherapy after progression
on kinase inhibitors.107
Further approaches to BRAF/MEKi combination
include trials with encorafenib and binimetinib. Encorafe-
nib is a BRAFi with increased affinity to BRAF and thus
a longer binding time. Results from a phase I/II clinical trial
confirm a RR and PFS consistent with other BRAF/MEKi
combinations (mPFS 11.3 months [95% CI 7.4e14.6]),
with a considerably higher PFS in the baseline low LDH
group, going along with previous reports.109 A phase II trial
evaluating encorafenib and binimetinib alone and in combi-
nation with a third agent after progression (LOGIC-2), re-
ported an ORR of 68% for BRAF- and MEK-inhibitor
na€ıve patients, and 20% for non-na€ıve patients, which is
in accordance to results from other combinations.110 Recent
results from a phase III trial demonstrated a mPFS of 14.9
months vs. 7.3 months for vemurafenib monotherapy with a
HR of 0.54 [95% CI 0.41e0.71, p < 0.001] vs. 9.6 months
for encorafenib monotherapy with a HR of 0.75 [95% CI
0.56e1.00, p ¼ 0.051].111
In general, similar percentages of grade 3-4 adverse
events were seen in both monotherapy and combination
treatment. Dabrafenib and trametinib combination treat-
ment was associated with a higher frequency of pyrexia
than BRAFi monotherapy (up to 71% of patients). Further-
more, gastrointestinal toxic effects (diarrhea, nausea, vom-
iting) were seen more frequently with combination.99,100,102
Acneiform dermatitis, a common dose-limiting effect of
trametinib, was reduced in combination treatment.99 Toxic
events related to paradoxical MAPK pathway activation
like cutaneous SCCs and hyperkeratosis were significantly
lower in all combination treatments.99,100,102,104,112
The vemurafenib/cobimetinib combination is associated
with a higher frequency of central serous retinopathy,
gastrointestinal events (diarrhea, nausea, vomiting),
photosensitivity (due to the UVA-absorbing property of
the molecule),85 elevated aminotransferase levels, and an
increased creatine kinase level, with the majority of events
being grade 1e2. Keratoacanthomas, cutaneous SCC, alo-
pecia and arthralgias were observed in a lower frequency
with the combination. The frequency of clinically signifi-
cant cardiac events (QT-interval prolongation and
decreased ejection fraction) was low and similar in mono-
and combination therapy, as was pyrexia.104 Encorafenib
and binimetinib exhibited lower rates of pyrexia and photo-
sensitivity than other combinations.109
Class effects of MEK blockade include reversible,
asymptomatic elevated CK levels, observed in 30% of pa-
tients in cobimetinib/vemurafenib,104 as well as transient
drug-induced retinopathy, which is reversible, and can be
managed with dose reduction or withdrawal of MEKi.
Overall, combination of BRAF and MEK inhibition is
well tolerated and markedly delays the onset of resistance
compared to BRAF monotherapy. Combination treatment
consistently exhibited a lower rate of secondary cutaneous
cancers compared to single drug BRAF inhibi-
tion.99,100,102,104 Long term follow-up confirms the safety,
response and tolerability and suggests long-term benefit
without progression for a subset of patients (approx.
20%).107 Thus, combination of a BRAF- and MEKi is
considered the current standard of care for patients
harboring BRAF mutations.
Perspective
As mentioned above, the combination of a selective
BRAF- and MEKi is the current standard of care. However,
about 80% of patients eventually develop resistance, most
notably patients with high LDH at baseline.107 Prolonged
responses may be achieved by adding additional molecules
(triple therapy). The choice of the third molecule could
potentially be determined by individual genetic alterations.7
Possible candidates include inhibitors of cell cycle control,
the PI3K-AKT pathway, and the surface receptors MET and
fibroblast growth factor receptor (FGFR).
Cyclin-dependent kinases (CDKs) are serine/threonine
kinases regulating cell division by promoting transitions
through the cell cycle (CDK 4, 6, 2 and 1) and modulating
transcription in response to several intra- and extracellular
signals.113 A number of alterations concerning the
p16INK4A:cyclin D-CDK4/6:RB pathway have been re-
ported in melanoma.7,114 Several different orally bioavail-
able, specific small molecule inhibitors of CDK 4 and 6
are currently available. By targeting CDK4/6, they inhibit
phosphorylation of retinoblastoma protein and thus prevent
CDK-mediated G1-S phase transition. Thus, the cell cycle
is arrested in the G1 phase, thereby suppressing DNA syn-
thesis and inhibiting growth of cancer cells.
PI3Ks are intracellular signaling proteins important for
inhibition of apoptosis. The PI3K-AKT pathway was found
to be activated in human cancers through multiple
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mechanisms, including activating PI3K mutations,
decreased expression or function of PI3K suppressors (e.g.
PTEN ), PI3K amplifications and activation of upstream on-
cogenes (e.g. NRAS ) or receptors.7,115,116 Thus, multiple
classes of inhibitors are available, including PI3K inhibitors
(pan-isoform and isoform-specific), dual PI3K-mTOR in-
hibitors, AKT inhibitors and mTOR (mTORC1 and dual
mTORC1/2) inhibitors. Several molecules are available for
each class, many of which are currently evaluated in clinical
trials.116 Initial trials combining Pan-PI3K-inhibitors with
BRAF- and MEK-inhibitors have shown exceptionally
high toxicity.
Most melanoma patients harboring a BRAF mutation
seem to have some degree of innate resistance to kinase in-
hibitors. One major cause of innate resistance is stroma-
mediated resistance. Secretion of hepatocyte growth factor
(HGF) by stromal cells leads to activation of the HGF-
receptor MET, reactivation of the MAPK and the PI3K-
AKT signaling pathways and immediate resistance to RAF
inhibition.117 Consequently, dual inhibition of RAF and either
MET or HGF serves as a potential strategy to counteract this
mechanism of resistance. Several small molecule, highly spe-
cific inhibitors of MET and HGF are currently being tested.
Human fibroblast growth factors (FGF) are polypeptide
growth factors that transduce signals by binding to trans-
membrane receptor tyrosine kinases, the FGFR,118,119 which
then activate important cellular pathways including the
MAPK and PI3K pathway.120 Amongst others, FGFs control
cell proliferation, migration, angiogenesis, apoptosis and dif-
ferentiation, and further play a role in neoangiogenesis, thus
aiding tumor vascularization.121 Hyperactivation of FGFR
signaling seems to be associated with growth and progres-
sion in several different types of cancers.122 FGF2 is overex-
pressed on melanoma cells, but not on normal
melanocytes,123 and has been linked to tumor progression
in multiple malignancies, including melanoma.122 BGJ398
is an orally bioavailable, potent and selective inhibitor of
FGFRs that selectively suppresses FGFR signaling and pro-
liferation in tumor cells with FGFR dependency and has an
effect on endothelial cells by blocking FGF-induced angio-
genesis, hence inhibiting tumor growth.124,125 It is currently
being tested in clinical trials.
Two ongoing trials are investigating the addition of a
third molecule to encorafenib and binimetinib. A phase
Ib/II trial is comparing the efficacy and safety of the triple
therapy with encorafenib, binimetinib and ribociclib (a
CDK4/6 inhibitor) versus the dual combination of encora-
fenib and binimetinib in BRAF-mutant metastatic mela-
noma (NCT01543698). A phase II clinical trial (LOGIC
2, NCT02159066) adds a third molecule based on an indi-
vidual profile of molecular alterations once patients prog-
ress on encorafenib and binimetinib.
Moreover, the combination of MAPK inhibitors
with immunotherapy represents an interesting therapy
approach.126 Upregulation of melanocyte differentiation
antigen expression by BRAF-mutant melanoma cells upon
exposure to BRAF inhibitors has been described in several
studies in human melanoma cell lines and melanoma bio-
psies.127e129 Similarly, MEKi also seem to increase expres-
sion of melanocyte differentiation antigens,127,130
improving antigen-specific T-cell recognition.127,131 This
might result in increased lymphocyte homing to tumor
cells, especially CD8þ cells, and improved lymphocyte
function.126,128 Thus, efficacy of immunotherapy may be
augmented by combination with kinase inhibitors. Howev-
er, long-term effects are uncertain and initial clinical trials
showed increased toxicity: a phase I study combining ve-
murafenib and ipilimumab was stopped due to liver
toxicity,132 while a phase I dose-finding trial investigating
the safety of the combination of dabrafenib and ipilimumab
and triple therapy with dabrafenib, trametinib, and ipilimu-
mab had to close the triple arm as intestinal perforation
(following colitis) was seen in 2 out of 7 total patients.133
Targeted- and immunotherapy have both demonstrated
impressive efficacy with profound impact on survival. To
date, there are no convincing clinical data available that
would justify one of the two as an established first line. Since
this question is highly relevant for daily clinical care, careful
investigation in further clinical trials is needed.
Targeted therapy with a BRAF- and MEKi combination is
a reasonable first- and second line treatment option in BRAF-
mutated melanoma. Furthermore, MEK inhibition appears
promising in NRAS mutated patients, especially after failure
of immunotherapy. New combination trials are ongoing.
There is justified optimism that these combinations will
further improve the outcome in BRAF- and NRAS-mutated
melanoma, but possibly also in other populations such as
NF1-, GNA- and GNAQ-mutated melanoma. Additional
benefit might be seen in the adjuvant and neoadjuvant setting.
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